Acquired Pelger-Huët anomaly in association with concomitant tacrolimus and mycophenolate mofetil in a liver transplant patient: A case report and review of the literature

Archives of Pathology and Laboratory Medicine

Volumn 130, Issue 1, 2006, Pages 93-96

  Etzell, Joan E ^a   Wang, Endi ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ANEMIA; BLOOD SMEAR; BONE MARROW BIOPSY; CASE REPORT; CELL SHAPE; CELL ULTRASTRUCTURE; CLINICAL FEATURE; DESENSITIZATION; DRUG DOSE REDUCTION; DRUG EFFECT; EPISTAXIS; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE DISORDER; LIVER TRANSPLANTATION; MALE; REVIEW; RISK FACTOR; SYMPTOM;

DESENSITIZATION, IMMUNOLOGIC; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NEUTROPHILS; PELGER-HUET ANOMALY; POSTOPERATIVE COMPLICATIONS; RECOVERY OF FUNCTION; TACROLIMUS;

EID: 30444453664     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Skubitz K. Qualitative disorders of leukocytes. In: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B, eds. Wintrobe's Clinical Hematology. 11th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2004:1802-1803.
2. Constantino BT. Pelger-Huët anomaly-morphology, mechanism, and significance in the peripheral blood film. Lab Med 2005;36:103-107.
3. Condo H, Okamura C, Osaki K, et al. Acquired Pelger-Huët anomaly in association with concomitant tacrolimus and fluconazole therapy following allogeneic bone marrow transplantation. Bone J Marrow Transplant. 2000;26:1255-1257.
4. Banerjee R, Halil O, Bain BJ, et al. Neutrophil dysplasia caused by mycophenolate mofetil. Transplantation. 2000;70:1608-1610.
5. Asmis LM, Hadaya K, Majno P, et al. Acquired and reversible Pelger-Huët anomaly of polymorphonuclear neutrophils in three transplant patients receiving mycophenolate mofetil therapy. Am J Hematol. 2003;73:244-248.
6. Kennedy GA, Kay TD, Johnson DW, et al. Neutrophil dysplasia characterised by a pseudo-Pelger-Huët anomaly occurring with the use of mycophenolate mofetil and ganciclovir following renal transplantation: a report of five cases. Pathology. 2002;34:263-266.
7. Dobrolet NC, Webber SA, Blatt J, et al. Hematologic abnormalities in children and young adults receiving tacrolimus-based immunosuppression following cardiothoracic transplantation. Pediatr Transplant. 2001;5:125-131.
8. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant. 2004;4:237-243.
9. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85-118.
10. Glander P, Hambach P, Braun KP, et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant. 2004;4:2045-2051.
11. Perry I, Neuberger J. Immunosuppression: towards a logical approach in liver transplantation. Clin Exp Immunol. 2005;139:2-10.
12. Hoffmann K, Dreger CK, Olins AL, et al. Mutations in the gene encoding the lamin B receptor produce an altered nuclear morphology in granulocytes (Pelger-Huët anomaly). Nat Genet. 2002;31:410-414.
13. Best S, Salvati F, Kallo J, et al. Lamin B-receptor mutations in Pelger-Huët anomaly. Br J Haematol. 2003;123:542-544.